The Acromegaly market report provides current treatment practices, emerging drugs, Acromegaly market share of the individual therapies, current and forecasted Acromegaly market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Acromegaly treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Acromegaly Disease Understanding and Treatment Algorithm
The Acromegaly market report gives a thorough understanding of the Acromegaly by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Acromegaly.
Treatment
It covers the details of conventional and current medical therapies available in the Acromegaly market for the treatment of the condition. It also provides Acromegaly treatment algorithms and guidelines in the United States, Europe, and Japan.
Acromegaly Epidemiology
The Acromegaly epidemiology division provide insights about historical and current Acromegaly patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Acromegaly epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Acromegaly Epidemiology
The epidemiology segment also provides the Acromegaly epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Acromegaly Drug Chapters
Drug chapter segment of the Acromegaly report encloses the detailed analysis of Acromegaly marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acromegaly clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Acromegaly treatment.
Acromegaly Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Acromegaly treatment.
Acromegaly Market Outlook
The Acromegaly market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acromegaly market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Acromegaly market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Acromegaly market in 7MM is expected to change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Acromegaly market in 7MM.
The United States Market Outlook
This section provides the total Acromegaly market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Acromegaly market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Acromegaly market size and market size by therapies in Japan is also mentioned.
Acromegaly Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Acromegaly market or expected to get launched in the market during the study period 2019-2032. The analysis covers Acromegaly market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acromegaly Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acromegaly key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acromegaly emerging therapies.
Reimbursement Scenario in Acromegaly
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL-Views
To keep up with current market trends, we take KOLs and SME's opinion working in Acromegaly domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acromegaly market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
The publisher performs Competitive and Market Intelligence analysis of the Acromegaly Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Acromegaly, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Acromegaly epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Acromegaly are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Acromegaly market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acromegaly market
Report Highlights
- In the coming years, Acromegaly market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Acromegaly. Launch of emerging therapies will significantly impact the Acromegaly market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acromegaly
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Acromegaly Report Insights
- Patient Population
- Therapeutic Approaches
- Acromegaly Pipeline Analysis
- Acromegaly Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Acromegaly Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Acromegaly Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Acromegaly Report Assessment
Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions Answered
Market Insights:
- What was the Acromegaly market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Acromegaly total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Acromegaly market size during the forecast period (2019-2032)?
- At what CAGR, the Acromegaly market is expected to grow in 7MM during the forecast period (2019-2032)?
- What would be the Acromegaly market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Acromegaly market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Acromegaly?
- What is the historical Acromegaly patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Acromegaly in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acromegaly?
- Out of all 7MM countries, which country would have the highest prevalent population of Acromegaly during the forecast period (2019-2032)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Acromegaly treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Acromegaly in the USA, Europe, and Japan?
- What are the Acromegaly marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Acromegaly?
- How many therapies are developed by each company for Acromegaly treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Acromegaly treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acromegaly therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acromegaly and their status?
- What are the key designations that have been granted for the emerging therapies for Acromegaly?
- What are the global historical and forecasted market of Acromegaly?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Acromegaly market
- To understand the future market competition in the Acromegaly market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Acromegaly in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Acromegaly market
- To understand the future market competition in the Acromegaly market
Table of Contents
Executive Summary
Acromegaly Epidemiology
The epidemiology segment also provides the Acromegaly epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Acromegaly Drug Chapters
The drug chapter segment of the Acromegaly report encloses the detailed analysis of Acromegaly marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Acromegaly clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Acromegaly Marketed Drugs
Somatuline Depot (lanreotide acetate): Ipsen Biopharmaceuticals
Somatuline Depot (lanreotide) Injection is approved for the long-term treatment of Acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. It is also approved for neuroendocrine tumors along with carcinoid syndrome. It contains the drug substance lanreotide acetate, a synthetic octapeptide with biological activity similar to naturally occurring somatostatin, water for injection and acetic acid (for pH adjustment). Somatuline Depot is available as sterile, ready-to-use, single-use prefilled syringes containing lanreotide acetate supersaturated bulk solution of 24.6% w/w lanreotide base. Somatuline is marketed as Somatuline Depot within the United States and as Somatuline Autogel in other countries where it has marketing authorization, including the various EU Member States.
Products details in the report...
Somavert (Pegvisomant): Pharmacia & Upjohn/Pfizer
Somavert (pegvisomant) is an injection developed by Pharmacia & Upjohn for the treatment of Acromegaly. It is an analog of human growth hormone (GH) that has been structurally altered to act as a GH receptor antagonist. Pegvisomant is a protein of recombinant DNA origin containing 191 amino acid residues to which many polyethylene glycol (PEG) polymers are covalently bound (predominantly 4 to 6 PEG/protein molecule). Pegvisomant is synthesized by a specific strain of Escherichia coli bacteria that has been genetically modified by the addition of a plasmid that carries a gene for GH receptor antagonist. Biological potency is determined using a cell proliferation bioassay. Somavert is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.
Products details in the report...
Sandostatin LAR Depot: Novartis Pharmaceuticals
Sandostatin LAR Depot is an approved product by Novartis Pharmaceuticals in the form of injectable suspension. Octreotide is the acetate salt of a cyclic octapeptide. The drug is a cyclic octapeptide prepared as a clear sterile solution of the octreotide acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (SC) or intravenous (IV) injection. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Sandostatin LAR Depot is available in a vial containing the sterile drug product, which when mixed with diluent, becomes a suspension that is given as a monthly intragluteal injection. Sandostatin LAR is a somatostatin analog indicated for the treatment of Acromegaly, Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors and Profuse watery diarrhea associated with VIP-secreting tumors.
Products details in the report...
Acromegaly Emerging Drugs
IONIS-GHR-LRx: Ionis Pharmaceuticals
IONIS-GHR-LRx is a Ligand-Conjugated Antisense (LICA) drug designed to reduce the production of the growth hormone receptor, or GHr, to decrease the circulating level of insulin-like growth factor-1 or IGF-1. IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. When produced in excess, IGF-1 results in Acromegaly. It is being developed to be administered via the subcutaneous route.
Ionis Pharmaceuticals has already completed a Phase I, double-blind, placebo-controlled, dose-escalation study of IONIS-GHR-LRx in healthy volunteers. In this study, IONIS-GHR-LRx demonstrated a favorable safety and tolerability profile. There were no reports of deaths, serious adverse events or adverse events that led to study discontinuation. This investigative drug candidate is in two Phase II clinical studies in Patients with acromegaly being treated with long-acting somatostatin receptor ligands (SRL).
Products details in the report...
Mycapssa (Octreotide Capsules): Chiasma Pharma
Mycapssa (Octreotide Capsules) is an investigational drug being developed by Chiasma Pharma for the maintenance treatment of Acromegaly. Chiasma had submitted an NDA in 2015 for Octreotide capsules. Octreotide capsules have been granted orphan designation in the US and the European Union for the potential treatment of acromegaly. Octreotide capsules were developed using Chiasma's proprietary Transient Permeability Enhancer (TPE) technology platform designed to facilitate gastrointestinal absorption of the unmodified drug into the bloodstream safely. The company completed an international Phase III trial of octreotide capsules. The NDA of the resubmission was accepted by the US FDA in January 2020 and the FDA assigned a Prescription Drug User-Fee Act (PDUFA) target action date of June 26, 2020. The company is also anticipating the top-line data from the MPOWERED (for EU approval) trial in the fourth quarter of 2020.
Products details in the report...
ATL1103: Antisense Therapeutics
ATL1103 (Atesidorsen) is a second-generation antisense drug being developed by Antisense Therapeutics. It is designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone-insulin-like growth factor‐I (IGF‐I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. The Company had already conducted a Phase II trial of ATL1103 with the trial has met its primary efficacy endpoint by showing a statistically significant average reduction in serum IGF-1 (sIGF-1) levels. It is being developed to be administered via the subcutaneous route.
The Company conducted a successful Phase II trial of ATL1103 with the trial met its primary efficacy endpoint by showing a statistically significant average reduction in sIGF-1 levels. The Company has also completed a high dose study of ATL1103 in adult patients with acromegaly in Australia.
In August 2019, the Company provided a market update on the status of the EAP confirming that to date the Company had been unable to obtain myTomorrows’ clearance for the importation of ATL1103 drug product. It is required to be approved to use in clinical trials in the EU. The Company stated that it would not apply further resources to the early access process for acromegaly.
Products details in the report...
Acromegaly Market Outlook
United States contributes to the major share of the Acromegaly market as compared to other countries, such as EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan. The high prevalence of Acromegaly in the United States is a major factor in stimulating market growth.
The current treatment method for acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas, and on reducing GH and IGF-1 levels to normal. Although, the primary treatment method for acromegaly is transsphenoidal surgery all the patients are not eligible for surgery. The cure rate of surgery is about 80% for microadenomas and 40-50% for macroadenomas. Those patients who are not eligible for surgery and those for whom surgery was failed to correct GH/IGF-1 hypersecretion, medical treatment with somatostatin analogs (SSAs), dopamine agonists (DA), growth hormone antagonists and/or radiotherapy can be used.
The approved therapies for the treatment acromegaly include Somatuline Depot (lanreotide acetate) injection, Somavert (pegvisomant), Sandostatin LAR Depot, and Signifor LAR (pasireotide).
According to the report, Acromegaly 7MM is expected to change in the study period 2017-2030.
Key Findings
- The therapeutic market of Acromegaly in the 7MM was USD 956.96 million in 2017 which is expected to increase with a CAGR of 5.73% for the study period 2017-2030
- The therapeutic market of Acromegaly in the United States was USD 517.76 million in the year 2017.
- The main therapeutic goal of the Acromegaly treatment market is to lower the risk of death by reducing the complication rate (progression rate) by safe treatment and controlling growth hormones.
- The therapeutic market of Acromegaly is dominated by SSAs, Dopamine Agonists and GHR Antagonists. The total market of these therapies was USD 736.77 million of SSAs, USD 186.29 million of GHR and USD 33.90 million of Dopamine Agonists in the year 2017 in the 7MM.
- Among the EU-5, Germany has the highest market size followed by the United Kingdom and France.
The United States Market Outlook
This section provides the total Acromegaly market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Acromegaly market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Acromegaly market size and market size by therapies in Japan are provided.
Acromegaly Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Acromegaly market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acromegaly market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acromegaly Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Acromegaly emerging therapies.
Reimbursement Scenario in Acromegaly
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In The report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Acromegaly market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Acromegaly, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Acromegaly epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Acromegaly is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Acromegaly market; historical and forecasted is included in The report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acromegaly market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Acromegaly market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Acromegaly. Launch of emerging therapies will significantly impact the Acromegaly market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Acromegaly Report Insights
- Patient Population
- Therapeutic Approaches
- Acromegaly Pipeline Analysis
- Acromegaly Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Acromegaly Report Key Strengths
- Eleven Years Forecast
- 7MM Coverage
- Acromegaly Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Acromegaly Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was the Acromegaly market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Acromegaly total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Acromegaly market size during the forecast period (2020-2030)?
- At what CAGR, the Acromegaly market is expected to grow at the 7MM level during the forecast period (2020-2030)?
- What would be the Acromegaly market outlook across the 7MM during the forecast period (2020-2030)?
- What would be the Acromegaly market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of Acromegaly?
- What is the historical Acromegaly patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Acromegaly at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acromegaly?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Acromegaly during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Acromegaly along with the approved therapy?
- What are the current treatment guidelines for the treatment of Acromegaly in the US and Europe?
- What are the Acromegaly marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Acromegaly?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Acromegaly?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acromegaly therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acromegaly and their status?
- What are the key designations that have been granted for the emerging therapies for Acromegaly?
- What are the 7MM historical and forecasted market of Acromegaly?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Acromegaly market.
- To understand the future market competition in the Acromegaly market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Acromegaly in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Acromegaly market.
- To understand the future market competition in the Acromegaly market.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amryt
- Chiasma
- Recordati
- Novartis Pharmaceuticals
- Sun Pharma
- Crinetics Pharmaceuticals
- Camurus
- Ionis Pharmaceuticals
